Kurzfassung

A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF SUBCUTANEOUSLY ADMINISTERED POZELIMAB IN COMBINATION WITH CEMDISIRAN OR CEMDISIRAN ALONE IN PARTICIPANTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION